Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048373 · ClinicalTrials.gov registry record · Phase 2
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
A Phase 2 study of Histiocytosis, Langerhans-Cell, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00048373 is a Phase 2 study of Histiocytosis, Langerhans-Cell that has completed, run by Baylor College of Medicine. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00048373, a Phase 2 study of Histiocytosis, Langerhans-Cell, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anticipate the subjects active participation to last up to one year.
Conditions Studied
Interventions
- DRUG Etanercept
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048373
The ClinicalTrials.gov registry entry for NCT00048373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Histiocytosis, Langerhans-Cell appearing as the primary indexed condition, and to 1 intervention - of which Etanercept is the first listed.
NCT00048373 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00048373 about?
NCT00048373 is a clinical study titled "Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL". The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anti...
What is the current status of trial NCT00048373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2001-10. Estimated completion is 2004-04.
What conditions does trial NCT00048373 study?
This clinical trial studies the following conditions: Histiocytosis, Langerhans-Cell.
What interventions are being tested in trial NCT00048373?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00048373?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048373 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytosis, Langerhans-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.